Should the McGill University Health Centre initiate an antiviral treatment programme for patients with chronic hepatitis C?
McGregor M
Record ID 32003000485
English
Authors' objectives:
Recent improvements in the treatment of hepatitis C have resulted in a higher cure rate and fewer side effects. There is at present a demand for the treatment of approximately 70 chronic hepatitis C patients, per year. This Technology Assessment was carried with the objective of helping the MUHC to decide whether a program for the antiviral treatment of chronic hepatitis C patients should be initiated or not. To estimate the effects of treatment it is first necessary to estimate the outcome of patients who remain untreated.
Authors' recommendations:
An MUHC program for the antiviral treatment of 70 patients per year should prevent the development of cirrhosis, with subsequent hepatic failure or hepatoma followed by death of 16, and possibly as many as 25 individuals per year, and cost the MUHC approximately $111,782. After an uncertain interval of possibly 12 years, the money saved would considerably exceed the costs of the programme.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.mcgill.ca/tau/publications/2002
Year Published:
2002
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antiviral Agents
- Costs and Cost Analysis
- Liver Cirrhosis
- Liver Failure
- Hepatitis C
Contact
Organisation Name:
Technology Assessment Unit of the McGill University Health Centre (MUHC)
Contact Address:
Technology Assessment Unit of the MUHC, Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, 5252 boul. de Maisonneuve, Bureau 3F.50, Montreal, Quebec H4A 3S5
Contact Name:
nandini.dendukuri@mcgill.ca
Contact Email:
nandini.dendukuri@mcgill.ca
Copyright:
Technology Assessment Unit of the McGill University Health Centre (MUHC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.